Whole Body Washing With Chlorhexidine for the Eradication of MRSA
|ClinicalTrials.gov Identifier: NCT00266448|
Recruitment Status : Completed
First Posted : December 16, 2005
Last Update Posted : December 16, 2005
|Condition or disease||Intervention/treatment||Phase|
|MRSA-Colonization||Drug: Chlorhexidine solution 4%||Phase 2|
The number and rate of infections due to meticillin-resistant Staphylococcus aureus (MRSA)is increasing world wide. Patients who are colonized with MRSA are the main source for further distribution. In addition colonization with MRSA is a precondition for infection.
Whole body washing with antiseptic solutions as part of eradication strategies for MRSA has been widely used. However, there is insufficient evidence to support use of topical antimicrobial therapy for eradicating of MRSA because treatment with antiseptic solution has never been compared to placebo.
Comparison: The efficacy of whole body washing in the control of MRSA was studied in a randomized, placebo-controlled, double-blinded clinical trial. The study treatment consisted of five days of whole body washing either with 4% chlorhexidine solution (verum) or with placebo. All patients received mupirocin nasal ointment and chlorhexidine mouth rinse. The outcome was evaluated 3, 4, 5, 9 and 30 days after treatment by swabs taken from several body site.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Value of Whole Body Washing With Chlorhexidine for the Eradication of MRSA – a Randomized, Placebo-Controlled, Double-Blinded Clinical Trial|
|Study Start Date :||January 2001|
|Study Completion Date :||April 2004|
- efficacy of a whole body treatment with chlorhexidine in eradicating overall MRSA carriage
- development of MRSA infection
- tolerance to the antiseptic whole body treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266448
|University Hospital Heidelberg|
|Heidelberg, Germany, 69120|
|Principal Investigator:||Constanze Wendt, MD, MSc||Hygiene-Institut University Hospital Heidelberg|